Predominance of Th17 over regulatory T-cells in pleural effusions of patients with lung cancer implicates a proinflammatory profile

Anticancer Research

Volumn 35, Issue 3, 2015, Pages 1529-1536

  Prado Garcia, Heriberto ^a   Romero Garcia, Susana ^a   Rumbo Nava, Uriel ^a   Lopez Gonzalez, Jose Sullivan ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

CD4+CD25+CD127low regulatory T cells; CD4+ROR t+ Th17 cells; Lung cancer; Pleural effusion

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 2; RETINOID RELATED ORPHAN RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; LUNG CANCER; LYMPHOCYTE DIFFERENTIATION; MALIGNANT NEOPLASTIC DISEASE; PLEURA EFFUSION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SUPERNATANT; TH17 CELL; TUBERCULOSIS; BIOSYNTHESIS; IMMUNOLOGY; LUNG TUMOR; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CYTOKINES; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; PLEURAL EFFUSION; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84924943736     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer Statistics. CA Cancer J Clin 58: 71-96, 2008.
2. Prado-Garcia H, Aguilar-Cazares D, Flores-Vergara H, Mandoki JJ and Lopez-Gonzalez JS: Effector, memory and naïve CD8+ T-cells in peripheral blood and pleural effusion from lung adenocarcinoma patients. Lung Cancer 47: 361-371, 2005.
3. Qin XJ, Shi HZ, Deng JM, Liang QL, Jiang J and Ye ZJ: CCL22 recruits CD4-positive CD25-positive regulatory T cells into malignant pleural effusion. Clin Cancer Res 15: 2231-2237, 2009.
4. + T-cells in malignant pleural effusion. J Immunol 185: 6348-6354, 2012.
5. Heffner JE: Diagnosis and management of malignant pleural effusions. Respirology 13: 5-20, 2008.
6. + regulatory T lymphocytes in malignant pleural effusion. Am J Respir Crit Care Med 172: 1434-1439, 2005.
7. DeLong P, Carroll RG, Henry AC, Tanaka T, Ahmad S, Leibowitz MS, Sterman DH, June CH, Albelda SM and Vonderheide RH: Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol Ther 4: 342-346, 2005.
8. + regulatory T cells suppress generation and differentiation of Th17 cells in human malignant pleural effusion via a LAP-dependent mechanism. Respir Res 12: 77, 2011.
9. Duan MC, Zhong XN, Liu GN and Wei JR: The Treg/Th17 paradigm in lung cancer. J Immunol Res 2014: 730380, 2014.
10. O'Garra A and Vieira P: Regulatory T cells and mechanisms of immune system control: Nat Med 10: 801-805, 2004.
11. Shen LS, Wang J, Shen DF, Yuan XL, Dong P, Li MX, Xue J, Zhang FM, Ge HL and Xu D: CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. Clin Immunol 131: 109-118, 2009.
12. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ and Littman DR: The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126: 1121-1133, 2006.
13. Annunziato F, Cosmi L, Liotta F, Maggi E and Romagnani S: Defining the human T helper 17 cell phenotype. Trends Immunol 33: 505-512, 2012.
14. Ye J, Livergood RS and Peng G: The role and regulation of human Th17 cells in tumor immunity. Am J Pathol 182: 10-20, 2013.
15. Chang SH, Mirabolfathinejad SG, Katta H, Cumpian AM, Gong L, Caetano MS, Moghaddam SJ and Dong C: T helper 17 cells play a critical pathogenic role in lung cancer. Proc Natl Acad Sci USA 111: 5664-5669, 2014.
16. Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Sautès-Fridman C, Fossiez F, Haicheur N, Fridman WH and Tartour E: Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 99: 2114-2121, 2002.
17. Sharma D, Eichelberg MR, Haag JD, Meilahn AL, Muelbl MJ, Schell K, Smits BM and Gould MN: Effective flow cytometric phenotyping of cells using minimal amounts of antibody. Biotechniques 53: 57-60, 2012.
18. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, Hoff ST, Andersen P, Reed SG, Morris SL, Roederer M and Seder RA: Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13: 843-850, 2007.
19. Wada J, Suzuki H, Fuchino R, Yamasaki A, Nagai S, Yanai K, Koga K, Nakamura M, Tanaka M, Morisaki T and Katano M: The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions. Anticancer Res 29: 881-888, 2009.
20. Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, Roncarolo MG and Levings MK: Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 19: 345-354, 2007.
21. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, Höpner S, Centonze D, Bernardi G, Dell'Acqua ML, Rossini PM, Battistini L, Rötzschke O and Falk K: Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110: 1225-1232, 2007.
22. Qiao D, Yang BY, Li L, Ma JJ, Zhang XL, Lao SH and Wu CY: ESAT-6-and CFP-10-specific Th1, Th22 and Th17 cells in tuberculous pleurisy may contribute to the local immune response against Mycobacterium tuberculosis infection. Scand J Immunol 73: 330-337, 2011.
23. Ye ZJ, Zhou Q, Du RH, Li X, Huang B and Shi HZ: Imbalance of Th17 cells and regulatory T cells in tuberculous pleural effusion. Clin Vaccine Immunol 18: 1608-1615, 2011.